Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin plus colchicine in heart failure with reduced ejection fraction
IRCT20111206008307N40Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Empagliflozin + colchicine with Empagliflozin control (2 arms). Primary endpoints: KCCQ grading scale, NYHA Functional Classification and 1 more. Started Nov 2022; status: completed.
02
Drugs
empagliflozincolchicine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on IRCT20111206008307N40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111206008307N40.